WO1999002133A2 - Topical application of a combination of benzoyl peroxide and a second active ingredient - Google Patents

Topical application of a combination of benzoyl peroxide and a second active ingredient Download PDF

Info

Publication number
WO1999002133A2
WO1999002133A2 PCT/EP1998/005046 EP9805046W WO9902133A2 WO 1999002133 A2 WO1999002133 A2 WO 1999002133A2 EP 9805046 W EP9805046 W EP 9805046W WO 9902133 A2 WO9902133 A2 WO 9902133A2
Authority
WO
WIPO (PCT)
Prior art keywords
composition
benzoyl peroxide
active ingredient
erythromycin
dispensing system
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP1998/005046
Other languages
French (fr)
Other versions
WO1999002133A3 (en
Inventor
Jean-Marie Lefevre
Luppo Edens
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Koninklijke DSM NV
DSM Delft BV
Original Assignee
Gist Brocades BV
DSM NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gist Brocades BV, DSM NV filed Critical Gist Brocades BV
Priority to JP2000501730A priority Critical patent/JP2001509477A/en
Priority to EP98945191A priority patent/EP0996428A2/en
Priority to AU92595/98A priority patent/AU9259598A/en
Priority to KR1020007000068A priority patent/KR20010015558A/en
Priority to BR9810985-5A priority patent/BR9810985A/en
Priority to US09/462,384 priority patent/US6448233B1/en
Publication of WO1999002133A2 publication Critical patent/WO1999002133A2/en
Publication of WO1999002133A3 publication Critical patent/WO1999002133A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents

Definitions

  • the present invention relates to the field of topical application of a combination of incompatible active ingredients, one being benzoyl peroxide.
  • Acne vulgaris is a skin disorder frequently occurring in young people. It is a disorder of the sebaceous follicles and is associated with the sharp increase in androgen production during adolescence. Hyperproduction of sebum and inflammation caused by proliferation of Propionibacterium acne are associated with this skin disorder. Erythromycin, or a mixture of erythromycin and clindamycin, is commonly used for the treatment of acne. However, propionibacterial resistance to these antibiotics is a growing concern because of its high incidence (Eady et al . (1993), Br. Med. J. 306: 555-556), the resistance to high concentrations of erythromycin and the cross resistance to clindamycin (Eady et al .
  • erythromycin can be stably formulated only in high concentrations of suitable solvents such as ethanol (Brisaert et al . (1996), Pharm. World Sci . 18: 182- 186) , whereas stability in formulations containing high levels of water is unacceptably low.
  • suitable solvents such as ethanol (Brisaert et al . (1996), Pharm. World Sci . 18: 182- 186)
  • stability in formulations containing high levels of water is unacceptably low.
  • topical application of high concentrations of ethanol is undesirable because of its irritancy to the skin.
  • benzoyl peroxide in solvents like ethanol is low. Long term stability of benzoyl peroxide can only be guaranteed in compositions providing a low benzoyl peroxide solubility (Chellquist and Gorman (1992), Phar . Res. 9: 1341-1346).
  • benzoyl peroxide is extremely reactive, because of instability of the 0-0 bond. Consequently, benzoyl peroxide can be expected to have a deleterious effect on the chemical stability of other compounds mixed with benzoyl peroxide.
  • the present invention provides a convenient solution to the above problems by applying a multicompartment dispensing system to enable separate containment of individual compositions, i.e. a first composition comprising benzoyl peroxide and a second composition comprising a second active ingredient.
  • said first and second composition generate a final composition when mixed upon delivery, said final composition being effective to apply benzoyl peroxide as well as the second active ingredient in an effective form.
  • the mixing of the individual compositions thereby may occur either in si tu or in the dispensing system prior to delivery.
  • the present invention further discloses a method to produce an effective composition comprising benzoyl peroxide and a second active ingredient by in si tu mixing of two individual compositions, each comprising a predetermined amount of either benzoyl peroxide or a second active ingredient .
  • the use of a multicompartment dispensing system according to the invention enables the preparation and use of separate compositions, on the one hand a composition comprising benzoyl peroxide as the active ingredient and on the other hand a composition comprising a second active ingredient.
  • These separate compositions are prepared in such a way that the individual requirements for stable formulation of each active ingredient are fulfilled.
  • the separate compositions are prepared in such a way that the final composition is effective to deliver the active ingredients present in each individual composition in a form suitable and effective for direct application.
  • the nature of the first and second composition are determined by on the one hand the stability requirements of each individual active ingredient and on the other hand the desired properties of the final composition.
  • the second active ingredient is an ingredient which may act in concert with or even synergistically with benzoyl peroxide.
  • Said second active ingredient for instance may be an antimicrobial agent, preferably an antibacterial or antifungal agent. More preferably, said antimicrobial agent is a acrolide antibiotic, such as erythromycin or natamycin, and/or an aminoglycoside antibiotic, such as clindamycin or lincomycin.
  • Another example of an antimicrobial agent which may be combined with benzoyl peroxide is a sphingoid base, like sphingosine or phytosphingosine (Bibel et, al (1992), J. Invest, Dermatol . 98: 269-273) .
  • a stable composition may be obtained when an active ingredient is formulated as a suspension formulation, e.g. a composition wherein the vehicle is selected to provide a low solubility of the active ingredient. Sedimentation of a suspended active ingredient in a suspension formulation is prevented by the use of a suitable viscosifying or thickening agent.
  • a stable composition of the active ingredient further may be obtained using a high concentration of a non-aqueous solvent in said composition. Examples of such non-aqueous solvents are ethanol or hydric solvents like polyethylene glycol, butylene glycol, propylene glycol or glycerol .
  • a stable composition of the active ingredient further may be obtained by dissolving a high concentration of the active ingredient in the solvent of choice.
  • the viscosity of the individual compositions is adjusted to the desired level using a viscosifying or thickening agent.
  • concentration of the viscosifying agent used mainly is determined by the solvent, the pH, and the weight and size of the particles to be kept in suspension. Conveniently, the concentration of the viscosifying agent may range from 0.1-3%. Desirable viscosities may range from 100 to 30.000 cps (Brookfield, 25 °C - 25 rpm) , preferably from 1000 to 10.000 cps. It is preferred that the two individual compositions present in the dispenser according to the invention have a substantially similar viscosity.
  • Carbomer viscosifiers like Carbopol 940 (B.F. Goodrich) and cellulose derivatives like hydroxypropylmethylcellulose, optionally in combination with colloidal magnesium silicate (Veegu ) .
  • Viegu colloidal magnesium silicate
  • viscosifying agents which may be considered include xanthans, Carbomer viscosifyers like Carbopol Ultrez 10 or carrageenans like Satia gum UTC 30 (SBI, Benelux) .
  • the concentration of the active ingredient in the stable composition typically depends on both the desired end concentration of said active ingredient in the final composition as well as on the ratio wherein the first and second composition are mixed to obtain the final composition.
  • the ratio in which the two individual compositions are delivered by the dispensing system can be adjusted as desired. Typically, said ratio may be adjusted to any value within a range varying from 1:1 to 1:50. Preferably, said ratio may vary from 1:2 to 1:20. To obtain a dilution of one composition into the other is especially advantageous in the case that one composition contains a solvent in a concentration which is to high for direct topical application.
  • a suitable benzoyl peroxide composition for use in the dispensing system according to the invention is for instance an aqueous suspension formulation comprising benzoyl peroxide in a concentration ranging from 2 to 30 % (w/v) .
  • end concentrations of benzoyl peroxide on the skin may range from 2% to 15%.
  • the nature of the composition comprising the second active ingredient will depend on the requirements for stable formulation of the second active ingredient.
  • Stable erythromycin compositions are for instance specified by Vandenbossche et al . (Int. J. Pharmaceutics, 67 (1991) : 195-199) .
  • erythromycin compositions 'containing high levels of ethanol are preferable (Brisaert et al . (1994), Farmaceutisch Tijdschrift voor Belgie, 1-2, 2-5) .
  • the use of pure ethanol as a solvent for erythromycin is also advantageous because erythromycin base can be dissolved in concentrations up to 30%.
  • stable erythromycin compositions are suspension formulations of erythromycin, suspended in for instance propylene glycol, PEG 400, isopropanol, or mixtures thereof.
  • Stable aqueous natamycin compositions are described for instance in European Patent Application EP 678241.
  • the stable natamycin compositions disclosed in EP 678241 are suspensions of natamycin crystals in an aqueous medium, wherein sedimentation of the crystals is prevented by the addition of a suitable viscosifying agent, such as xanthan or carrageenan. Additional suitable viscosifyers include Carbomers or related resins .
  • Stable aqueous clindamycin compositions are for instance specified by Oesterling (J. Pharm. Sciences (1970) 59: 63-67) .
  • maximum stability is obtained at a pH value of 3-5.
  • the nature of the final composition further may determine additional properties of one or both individual composition (s) .
  • the pH of the benzoyl peroxide composition and/or the composition comprising the second active ingredient may be adjusted to the desired pH value of the final composition.
  • a multicompartment dispenser containing a first composition comprising benzoyl peroxide and a second composition comprising erythromycin.
  • Said first composition comprises 5% (w/v) benzoyl peroxide suspended in an aqueous composition adjusted with sodium hydroxide to a pH of 8 - 8.5 and comprising Carbopol 940 as a viscosifying agent to reach a Brookfield viscosity between 500 and 5000 cps.
  • Said second composition comprises 30% (w/v) erythromycin dissolved in 96% ethanol and Carbopol Ultrez 10 as a viscosifyer.
  • the viscosity of the erythromycin composition is comparable to the viscosity of the benzoyl peroxide gel.
  • Said first and second composition are mixed in a ratio of nine parts first to one part second composition, resulting in a final composition having a concentration of about 5% benzoyl peroxide and 3% erythromycin.
  • the nature of the erythromycin composition i.e. dissolved in 96% ethanol, specifically requires a delivery ratio of both compositions which ensures a dilution of said erythromycin compostion in the final composition of at least about a factor 10. Since erythromycin is more active at an alkaline pH (Heilman and Herrell (1952), Proc .
  • the adjustment of the pH to a value of about 8.5 is desirable for optimal activity.
  • this pH value has a deleterious effect on erythromycin stability.
  • the use of a dispenser according to the invention ensures that this pH adjustment occurs only after delivery from the dispenser and mixing on the skin, whereby the final pH is brought about by the benzoyl peroxide composition.
  • the second composition comprises natamycin as the active ingredient.
  • natamycin The solubility of natamycin, and thus its antifungal effectiveness, is optimal in the higher or lower pH ranges, e.g. around pH 3. Contrary, its stability in these pH ranges is rather low. Therefore, the use of a dispenser according to the invention allows for the combination of a concentrated stable natamycin composition with a stable but acidic benzoyl peroxide composition.
  • the dispensing system used is not critical to the invention.
  • the present invention contemplates any dispensing system which allows for a separate containment as well as a simultaneous dosing (dispensing) of the individual compositions. Examples of suitable dispensing systems are given in WO 97/27841.
  • a preferred multicompartment dispensing system is a dispenser containing two differently- sized compartments. Such a dispenser enables the dispensing of unequal amounts of two different compositions.
  • the dispensing system according to the invention provides a covenient way to topically deliver a combination of benzoyl peroxide and a second active ingredient.
  • Benzamycin ® is a pharmaceutical product marketed by Dermik (USA) against serious forms of acne.
  • the product consists of a mixture of 3% erythromycin and 5% benzoyl peroxide. Owing to the chemical imcompatability of erythromycin and benzoyl peroxide, the product comes as two separate jars, one containing erythromycin and one containing a benzoyl peroxide gel. Prior to use, erythromycin and benzoyl peroxide have to be mixed and refrigerated to allow a maximal use period of 3 months by the patient. A two chamber dispenser was supplied by CosmoCair (Gist-brocades, Delft, the Netherlands).
  • This "Symbio” dispenser combines in one housing a normal and an air-free lotion pump, both activated by the same actuator. Each one of the two pumps is connected to its own individual chamber.
  • the air-free lotion pump is connected with a small cartridge equipped with a plunger in the bottom of the cartridge .
  • the other pump is connected with a diptube and dispenses the formulation from the largest chamber.
  • the dispenser is assembled, the filled cartridge is (partly) submerged in the formulation contained in the largest chamber. During storage and use, the formulations contained in the cartridge and the largest chamber are kept completely separated.
  • the dispenser Upon actuation, the dispenser delivers 0.4 grams of formulation, approx. 0.36 ml from the largest chamber and 0.04 ml from the cartridge. Both product streams are kept completely separated until they are ejected from the orifices of the dispenser.
  • the pump was primed to prepare for dispensing of the two formulations on the skin.
  • Manual mixing of the erythromycin concentrate with the co-dispensed benzoyl peroxide on the skin yielded a mixture containing 3% erythromycin and 5% benzoyl peroxide.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention discloses a multicompartment dispensing system separately containing a first composition comprising benzoyl peroxide and a second composition comprising a second active ingredient, preferably an antimicrobial agent. Said first and second composition generate a final composition when mixed upon dispensing, said final composition being effective to apply an effective combination of benzoyl peroxide and said second active ingredient.

Description

Topical application of a combination of benzoyl peroxide and a second active ingredient
Field of the invention
The present invention relates to the field of topical application of a combination of incompatible active ingredients, one being benzoyl peroxide.
Background of the invention
Acne vulgaris is a skin disorder frequently occurring in young people. It is a disorder of the sebaceous follicles and is associated with the sharp increase in androgen production during adolescence. Hyperproduction of sebum and inflammation caused by proliferation of Propionibacterium acne are associated with this skin disorder. Erythromycin, or a mixture of erythromycin and clindamycin, is commonly used for the treatment of acne. However, propionibacterial resistance to these antibiotics is a growing concern because of its high incidence (Eady et al . (1993), Br. Med. J. 306: 555-556), the resistance to high concentrations of erythromycin and the cross resistance to clindamycin (Eady et al . (1989), Br. J. Dermatol . 121: 51-57) . One way to minimize the selective pressure towards resistancies is to combine the antibiotic with benzoyl peroxide . Benzoyl peroxide is clinically effective because of its bactericidal activity against Propionibacterium acnes as well as through its mild keratinolytic effect.
Unfortunately, several factors hamper the development of convenient topical formulations containing both erythromycin as well as benzoylperoxide .
For example, erythromycin can be stably formulated only in high concentrations of suitable solvents such as ethanol (Brisaert et al . (1996), Pharm. World Sci . 18: 182- 186) , whereas stability in formulations containing high levels of water is unacceptably low. However, topical application of high concentrations of ethanol is undesirable because of its irritancy to the skin.
In contrast, the stability of benzoyl peroxide in solvents like ethanol is low. Long term stability of benzoyl peroxide can only be guaranteed in compositions providing a low benzoyl peroxide solubility (Chellquist and Gorman (1992), Phar . Res. 9: 1341-1346). In addition, benzoyl peroxide is extremely reactive, because of instability of the 0-0 bond. Consequently, benzoyl peroxide can be expected to have a deleterious effect on the chemical stability of other compounds mixed with benzoyl peroxide.
Currently, for topical application of a combination of benzoyl peroxide and erythromycin, a suitable solvent has to be added to both compounds being individually packed as a powder, whereupon the resulting solution in turn has to be mixed into a topical gel. It is highly desirable to avail of a less cumbersome method to apply these compounds.
Description of the invention
The present invention provides a convenient solution to the above problems by applying a multicompartment dispensing system to enable separate containment of individual compositions, i.e. a first composition comprising benzoyl peroxide and a second composition comprising a second active ingredient. According to the invention, said first and second composition generate a final composition when mixed upon delivery, said final composition being effective to apply benzoyl peroxide as well as the second active ingredient in an effective form. The mixing of the individual compositions thereby may occur either in si tu or in the dispensing system prior to delivery.
The present invention further discloses a method to produce an effective composition comprising benzoyl peroxide and a second active ingredient by in si tu mixing of two individual compositions, each comprising a predetermined amount of either benzoyl peroxide or a second active ingredient . The use of a multicompartment dispensing system according to the invention enables the preparation and use of separate compositions, on the one hand a composition comprising benzoyl peroxide as the active ingredient and on the other hand a composition comprising a second active ingredient. These separate compositions are prepared in such a way that the individual requirements for stable formulation of each active ingredient are fulfilled. In addition, the separate compositions are prepared in such a way that the final composition is effective to deliver the active ingredients present in each individual composition in a form suitable and effective for direct application.
Thus, the nature of the first and second composition are determined by on the one hand the stability requirements of each individual active ingredient and on the other hand the desired properties of the final composition.
The second active ingredient is an ingredient which may act in concert with or even synergistically with benzoyl peroxide. Said second active ingredient for instance may be an antimicrobial agent, preferably an antibacterial or antifungal agent. More preferably, said antimicrobial agent is a acrolide antibiotic, such as erythromycin or natamycin, and/or an aminoglycoside antibiotic, such as clindamycin or lincomycin. Another example of an antimicrobial agent which may be combined with benzoyl peroxide is a sphingoid base, like sphingosine or phytosphingosine (Bibel et, al (1992), J. Invest, Dermatol . 98: 269-273) .
Typically, a stable composition may be obtained when an active ingredient is formulated as a suspension formulation, e.g. a composition wherein the vehicle is selected to provide a low solubility of the active ingredient. Sedimentation of a suspended active ingredient in a suspension formulation is prevented by the use of a suitable viscosifying or thickening agent. A stable composition of the active ingredient further may be obtained using a high concentration of a non-aqueous solvent in said composition. Examples of such non-aqueous solvents are ethanol or hydric solvents like polyethylene glycol, butylene glycol, propylene glycol or glycerol . A stable composition of the active ingredient further may be obtained by dissolving a high concentration of the active ingredient in the solvent of choice. The viscosity of the individual compositions is adjusted to the desired level using a viscosifying or thickening agent. The concentration of the viscosifying agent used mainly is determined by the solvent, the pH, and the weight and size of the particles to be kept in suspension. Conveniently, the concentration of the viscosifying agent may range from 0.1-3%. Desirable viscosities may range from 100 to 30.000 cps (Brookfield, 25 °C - 25 rpm) , preferably from 1000 to 10.000 cps. It is preferred that the two individual compositions present in the dispenser according to the invention have a substantially similar viscosity.
Examples of viscosifying agents for gellifying an aqueous suspension composition include Carbomer viscosifiers like Carbopol 940 (B.F. Goodrich) and cellulose derivatives like hydroxypropylmethylcellulose, optionally in combination with colloidal magnesium silicate (Veegu ) . To stabilize suspensions containing particles and/or containing high concentrations of ethanol or hydric solvents like polyethylene glycol, butylene glycol, propylene glycol or glycerol, viscosifying agents which may be considered include xanthans, Carbomer viscosifyers like Carbopol Ultrez 10 or carrageenans like Satia gum UTC 30 (SBI, Benelux) .
The concentration of the active ingredient in the stable composition typically depends on both the desired end concentration of said active ingredient in the final composition as well as on the ratio wherein the first and second composition are mixed to obtain the final composition.
The ratio in which the two individual compositions are delivered by the dispensing system can be adjusted as desired. Typically, said ratio may be adjusted to any value within a range varying from 1:1 to 1:50. Preferably, said ratio may vary from 1:2 to 1:20. To obtain a dilution of one composition into the other is especially advantageous in the case that one composition contains a solvent in a concentration which is to high for direct topical application. A suitable benzoyl peroxide composition for use in the dispensing system according to the invention is for instance an aqueous suspension formulation comprising benzoyl peroxide in a concentration ranging from 2 to 30 % (w/v) .
Suitable formulations guaranteeing long term stability of benzoyl peroxide compositions at elevated temperature conditions are given by e.g. Chellquist and Gorman ( supra) and Bollinger et al . (J. Pharm. Sci . 66 (1977): 718-722).
Typically, end concentrations of benzoyl peroxide on the skin may range from 2% to 15%. The nature of the composition comprising the second active ingredient will depend on the requirements for stable formulation of the second active ingredient.
Stable erythromycin compositions are for instance specified by Vandenbossche et al . (Int. J. Pharmaceutics, 67 (1991) : 195-199) . For long term stability at elevated temperatures erythromycin compositions 'containing high levels of ethanol are preferable (Brisaert et al . (1994), Farmaceutisch Tijdschrift voor Belgie, 1-2, 2-5) . The use of pure ethanol as a solvent for erythromycin is also advantageous because erythromycin base can be dissolved in concentrations up to 30%. Alternatively, stable erythromycin compositions are suspension formulations of erythromycin, suspended in for instance propylene glycol, PEG 400, isopropanol, or mixtures thereof. Stable aqueous natamycin compositions are described for instance in European Patent Application EP 678241. The stable natamycin compositions disclosed in EP 678241 are suspensions of natamycin crystals in an aqueous medium, wherein sedimentation of the crystals is prevented by the addition of a suitable viscosifying agent, such as xanthan or carrageenan. Additional suitable viscosifyers include Carbomers or related resins .
Stable aqueous clindamycin compositions are for instance specified by Oesterling (J. Pharm. Sciences (1970) 59: 63-67) . Using clindamycin, maximum stability is obtained at a pH value of 3-5.
The nature of the final composition further may determine additional properties of one or both individual composition (s) . For instance, the pH of the benzoyl peroxide composition and/or the composition comprising the second active ingredient may be adjusted to the desired pH value of the final composition.
In a preferred embodiment of the invention, a multicompartment dispenser is provided containing a first composition comprising benzoyl peroxide and a second composition comprising erythromycin. Said first composition comprises 5% (w/v) benzoyl peroxide suspended in an aqueous composition adjusted with sodium hydroxide to a pH of 8 - 8.5 and comprising Carbopol 940 as a viscosifying agent to reach a Brookfield viscosity between 500 and 5000 cps. Said second composition comprises 30% (w/v) erythromycin dissolved in 96% ethanol and Carbopol Ultrez 10 as a viscosifyer. Preferably, the viscosity of the erythromycin composition is comparable to the viscosity of the benzoyl peroxide gel. Said first and second composition are mixed in a ratio of nine parts first to one part second composition, resulting in a final composition having a concentration of about 5% benzoyl peroxide and 3% erythromycin. In this embodiment, the nature of the erythromycin composition, i.e. dissolved in 96% ethanol, specifically requires a delivery ratio of both compositions which ensures a dilution of said erythromycin compostion in the final composition of at least about a factor 10. Since erythromycin is more active at an alkaline pH (Heilman and Herrell (1952), Proc . Staff Meetings Mayo Clinic 27: 285-304), the adjustment of the pH to a value of about 8.5 is desirable for optimal activity. However, this pH value has a deleterious effect on erythromycin stability. The use of a dispenser according to the invention ensures that this pH adjustment occurs only after delivery from the dispenser and mixing on the skin, whereby the final pH is brought about by the benzoyl peroxide composition. In a further embodiment of the invention, the second composition comprises natamycin as the active ingredient.
The solubility of natamycin, and thus its antifungal effectiveness, is optimal in the higher or lower pH ranges, e.g. around pH 3. Contrary, its stability in these pH ranges is rather low. Therefore, the use of a dispenser according to the invention allows for the combination of a concentrated stable natamycin composition with a stable but acidic benzoyl peroxide composition. The dispensing system used is not critical to the invention. The present invention contemplates any dispensing system which allows for a separate containment as well as a simultaneous dosing (dispensing) of the individual compositions. Examples of suitable dispensing systems are given in WO 97/27841. A preferred multicompartment dispensing system is a dispenser containing two differently- sized compartments. Such a dispenser enables the dispensing of unequal amounts of two different compositions.
Care should be taken to use metal parts which are teflon-coated or nylon-coated (Rilsan process) , since benzoyl peroxide is a rather corrosive compound .
The dispensing system according to the invention provides a covenient way to topically deliver a combination of benzoyl peroxide and a second active ingredient.
Example 1 Topical application of benzoyl peroxide and erythromycin
Benzamycin® is a pharmaceutical product marketed by Dermik (USA) against serious forms of acne. The product consists of a mixture of 3% erythromycin and 5% benzoyl peroxide. Owing to the chemical imcompatability of erythromycin and benzoyl peroxide, the product comes as two separate jars, one containing erythromycin and one containing a benzoyl peroxide gel. Prior to use, erythromycin and benzoyl peroxide have to be mixed and refrigerated to allow a maximal use period of 3 months by the patient. A two chamber dispenser was supplied by CosmoCair (Gist-brocades, Delft, the Netherlands). This "Symbio" dispenser combines in one housing a normal and an air-free lotion pump, both activated by the same actuator. Each one of the two pumps is connected to its own individual chamber. The air-free lotion pump is connected with a small cartridge equipped with a plunger in the bottom of the cartridge . The other pump is connected with a diptube and dispenses the formulation from the largest chamber. When the dispenser is assembled, the filled cartridge is (partly) submerged in the formulation contained in the largest chamber. During storage and use, the formulations contained in the cartridge and the largest chamber are kept completely separated.
Upon actuation, the dispenser delivers 0.4 grams of formulation, approx. 0.36 ml from the largest chamber and 0.04 ml from the cartridge. Both product streams are kept completely separated until they are ejected from the orifices of the dispenser.
To mimic Benzamycin® in terms of final concentrations of benzoyl peroxide and erythromycin on the skin, stable formulations of benzoyl peroxide and erythromycin were used to fill the two compartments of the Symbio dispenser.
To prepare a slightly viscous suspension of benzoyl peroxide, 2.0 grams of Carbopol Ultrez 10 (B.F. Goodrich) 5 was carefully added to 450 ml of water. Subsequently 60 grams of aceton were added as well as 43.7 grams of benzoyl peroxide (Genfarma, the Netherlands) . Using 8N NaOH, the pH of the solution was raised to pH 8.0 and water was added to obtain a final volume of 600 grams. Finally the suspension o was homogenized with an Ultra-turrax. The next morning the suspension was centrifugated for 10 minutes at 5000 rpm in a Sorvall centrifuge to remove any air bubbles, if necessary carefully homogenized again and filled in the largest chamber of the dispenser. 5 To prepare a 10 -times concentrated solution of erythromycin, 20 grams butylene glycol, 1.0 grams Carpobol
Ultrez 10 and 49 grams of absolute ethanol were added to a glass beaker. Subsequently 30 grams of erythromycin
(Genfarma, the Netherlands) was added and the mixture was mixed at 40 °C until a clear solution was obtained. Finally this solution was centrifuged to remove any air bubbles and filled into a cartridge. To close the cartridge, the plastic plunger was applied in such a way that no residual air was left between the erythromycin concentrate and the plunger.
After attachment of the filled cartridge to the airfree micropump and assembly of the pumphead with the benzoyl peroxide filled container, the pump was primed to prepare for dispensing of the two formulations on the skin. Manual mixing of the erythromycin concentrate with the co-dispensed benzoyl peroxide on the skin yielded a mixture containing 3% erythromycin and 5% benzoyl peroxide.

Claims

Claims
1. A multicompartment dispensing system separately containing a first composition comprising benzoyl peroxide s and a second composition comprising a second active ingredient, said first and second composition generating a final composition when mixed upon dispensing, and said final composition being effective to apply a combination of benzoyl peroxide and said second active ingredient. 0
2. The dispensing system of claim 1, wherein the benzoyl peroxide composition is an aqueous suspension formulation, further comprising a viscosifying agent.
s 3. The dispensing system of claim 1 or 2 , wherein the second active ingredient is an antimicrobial agent.
4. The dispensing system of claim 3 wherein the antimicrobial agent is a macrolide and/or an aminoglycoside 0 antibiotic.
5. The dispensing system of claim 4, wherein the macrolide antibiotic is erythromycin or natamycin.
5 6. The dispensing system of claim 5, wherein the erythromycin composition is a solution of erythromycin in ethanol, further comprising a suitable viscosifying agent.
7. A method to produce an effective composition o comprising benzoyl peroxide and a second active ingredient by in si tu mixing of two individual compositions, each comprising a predetermined amount of either benzoyl peroxide or said second active ingredient.
PCT/EP1998/005046 1997-07-08 1998-07-08 Topical application of a combination of benzoyl peroxide and a second active ingredient Ceased WO1999002133A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
JP2000501730A JP2001509477A (en) 1997-07-08 1998-07-08 Topical application of a combination of benzoyl peroxide and a second active ingredient
EP98945191A EP0996428A2 (en) 1997-07-08 1998-07-08 Topical application of a combination of benzoyl peroxide and a second active ingredient
AU92595/98A AU9259598A (en) 1997-07-08 1998-07-08 Topical application of a combination of benzoyl peroxide and a second active ingredient
KR1020007000068A KR20010015558A (en) 1997-07-08 1998-07-08 Topical application of a combination of benzoyl peroxide and a second active ingredient
BR9810985-5A BR9810985A (en) 1997-07-08 1998-07-08 Topical application of a combination of benzoyl peroxide and a second active ingredient
US09/462,384 US6448233B1 (en) 1997-07-08 1998-07-08 Topical application of a combination of benzoyl peroxide and a second active ingredient

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP97202096.0 1997-07-08
EP97202096 1997-07-08

Publications (2)

Publication Number Publication Date
WO1999002133A2 true WO1999002133A2 (en) 1999-01-21
WO1999002133A3 WO1999002133A3 (en) 1999-04-01

Family

ID=8228523

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1998/005046 Ceased WO1999002133A2 (en) 1997-07-08 1998-07-08 Topical application of a combination of benzoyl peroxide and a second active ingredient

Country Status (8)

Country Link
US (1) US6448233B1 (en)
EP (1) EP0996428A2 (en)
JP (1) JP2001509477A (en)
KR (1) KR20010015558A (en)
CN (1) CN1133422C (en)
AU (1) AU9259598A (en)
BR (1) BR9810985A (en)
WO (1) WO1999002133A2 (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001091726A1 (en) * 2000-06-02 2001-12-06 Dermik International Holding Inc. Acne-treating composition
AU750192B2 (en) * 1998-02-20 2002-07-11 Procter & Gamble Company, The Method of making a slitted or particulate absorbent material
FR2820037A1 (en) * 2001-01-29 2002-08-02 Dermaconcept Jmc Veterinary dermatological composition used for treating dermal inflammation contains sphingoid base or its derivatives
FR2820038A1 (en) * 2001-01-29 2002-08-02 Dermaconcept Jmc Veterinary dermatological composition used for treating dermal bacterial and fungal infections in animals with fur contains sphingoid base or its salts or derivatives
WO2002047662A3 (en) * 2000-12-12 2003-03-13 Imaginitive Res Associates Inc Antibiotic/benzoyl peroxide dispenser
US6544562B2 (en) * 2001-06-25 2003-04-08 Blistex Inc. Acne treatment including dual-package system
US6774100B2 (en) 2000-12-06 2004-08-10 Imaginative Research Associates, Inc. Anhydrous creams, lotions and gels
US7060732B2 (en) 2000-12-12 2006-06-13 Imaginative Research Associates, Inc. Antibiotic/benzoyl peroxide dispenser

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060189552A1 (en) * 2000-12-12 2006-08-24 Mohan Vishnupad Dispenser for dispensing three or more actives
US20020193321A1 (en) * 2000-12-12 2002-12-19 Mohan Vishnupad Dual dispenser for aesthitically acceptable delivery of anhydrous skin treatment compositions
US20060014834A1 (en) * 2004-05-11 2006-01-19 Mohan Vishnupad Retinoid solutions and formulations made therefrom
US7662855B2 (en) * 2004-05-11 2010-02-16 Imaginative Research Associates, Inc. Retinoid solutions and formulations made therefrom
US7585504B2 (en) * 2004-10-22 2009-09-08 Medimmune, Llc High affinity antibodies against HMGB1 and methods of use thereof
CA2600547A1 (en) * 2005-03-10 2006-09-21 Jr Chem, Llc Benzoyl peroxide compositions and methods of use
KR101352187B1 (en) 2005-03-10 2014-02-17 제이알 켐, 엘엘씨 Stable organic peroxide compositions
WO2007005471A2 (en) * 2005-06-29 2007-01-11 Jr Chem, Llc Stable organic peroxide compositions
US7556820B2 (en) 2005-06-29 2009-07-07 Jr Chem, Llc Stable organic peroxide compositions
AR054805A1 (en) * 2005-06-29 2007-07-18 Stiefel Laboratories TOPICAL COMPOSITIONS FOR SKIN TREATMENT
WO2007002880A2 (en) * 2005-06-29 2007-01-04 Jr Chem, Llc Method of enhanced drug application
US20090306023A1 (en) * 2005-06-29 2009-12-10 Ramirez Jose E Stable organic peroxide compositions
US20070009607A1 (en) * 2005-07-11 2007-01-11 George Jones Antibacterial/anti-infalmmatory composition and method
WO2007076200A2 (en) * 2005-11-28 2007-07-05 Medimmune, Inc. Antagonists of hmgb1 and/or rage and methods of use thereof
WO2007092312A2 (en) * 2006-02-03 2007-08-16 Stiefel Laboratories, Inc. Topical skin treating compositions
ES2560540T3 (en) 2006-03-31 2016-02-19 Stiefel Research Australia Pty Ltd Foamable suspension gel
WO2008097850A1 (en) * 2007-02-02 2008-08-14 Warner Chilcott Company, Inc. Tretracycline compositions for topical administration
WO2008097851A1 (en) * 2007-02-02 2008-08-14 Warner Chilcott Company, Inc. Tetracycline compositions for topical administration
EP2123298A4 (en) * 2007-02-15 2011-09-28 Univ Fukuoka AGENT FOR SUPPRESSING REJECTION IN AN ORGAN TRANSPLANT COMPRISING ANTI-HMGB-1 ANTIBODY
US20080287373A1 (en) * 2007-05-17 2008-11-20 Popp Karl F Topical skin treating kits
KR101004519B1 (en) * 2008-12-08 2011-01-11 한국오므론전장주식회사 Trans bond structure
NZ598240A (en) 2009-07-16 2013-10-25 Stiefel Laboratories Tazarotene derivatives
US20110236503A1 (en) * 2010-03-23 2011-09-29 Cosmalabs International, Llc Topical Skincare Composition
US20120064135A1 (en) * 2010-09-15 2012-03-15 Norac Pharma Benzoyl Peroxide Composition, Methods for Making Same, and Pharmaceutical or Cosmetic Formulations Comprising Same, and Uses Thereof
WO2012153884A1 (en) * 2011-05-12 2012-11-15 (주)아모레퍼시픽 Composition having improved stability for ameliorating acne

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4497794A (en) 1980-12-08 1985-02-05 Dermik Laboratories, Inc. Erythromycin/benzoyl peroxide composition for the treatment of acne
IT1210608B (en) 1980-12-08 1989-09-14 Rorer Int Overseas COMPOSITION FOR TOPICAL ACNE TREATMENT
CA2015111A1 (en) 1990-04-23 1991-10-23 Tom Y. Woo New binary dispensor for the application of fluids, semi-fluids or semi-solids
TW203552B (en) * 1992-02-18 1993-04-11 J Baroody Lloyd Compositions of clindamycin and benzoyl peroxide for acne treatment
IT1263120B (en) 1992-05-05 1996-07-30 Gilardini Spa REAR-VIEW MIRROR FOR A VEHICLE EQUIPPED WITH A SUPPORT AND ORIENTATION DEVICE OF A REFLECTIVE SHEET OF THE PERFECT TYPE
US5538732A (en) * 1994-04-12 1996-07-23 Creative Products Resource, Inc. Medicated applicator sheet for topical drug delivery
US5922349A (en) 1995-09-28 1999-07-13 Schering Aktiengesellschaft Hormone replacement therapy method and hormone dispenser
KR100517060B1 (en) * 1996-01-31 2006-05-25 코스모페름 베.파우 Use of compositions comprising stabilized biologically effective compounds

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU750192B2 (en) * 1998-02-20 2002-07-11 Procter & Gamble Company, The Method of making a slitted or particulate absorbent material
WO2001091726A1 (en) * 2000-06-02 2001-12-06 Dermik International Holding Inc. Acne-treating composition
US6774100B2 (en) 2000-12-06 2004-08-10 Imaginative Research Associates, Inc. Anhydrous creams, lotions and gels
WO2002047662A3 (en) * 2000-12-12 2003-03-13 Imaginitive Res Associates Inc Antibiotic/benzoyl peroxide dispenser
US7060732B2 (en) 2000-12-12 2006-06-13 Imaginative Research Associates, Inc. Antibiotic/benzoyl peroxide dispenser
FR2820037A1 (en) * 2001-01-29 2002-08-02 Dermaconcept Jmc Veterinary dermatological composition used for treating dermal inflammation contains sphingoid base or its derivatives
FR2820038A1 (en) * 2001-01-29 2002-08-02 Dermaconcept Jmc Veterinary dermatological composition used for treating dermal bacterial and fungal infections in animals with fur contains sphingoid base or its salts or derivatives
US6544562B2 (en) * 2001-06-25 2003-04-08 Blistex Inc. Acne treatment including dual-package system
EP1503769A4 (en) * 2002-04-12 2009-07-15 Imaginative Res Associates Inc Antibiotic/benzoyl peroxide dispenser

Also Published As

Publication number Publication date
AU9259598A (en) 1999-02-08
KR20010015558A (en) 2001-02-26
WO1999002133A3 (en) 1999-04-01
CN1262616A (en) 2000-08-09
US6448233B1 (en) 2002-09-10
CN1133422C (en) 2004-01-07
JP2001509477A (en) 2001-07-24
BR9810985A (en) 2000-08-15
EP0996428A2 (en) 2000-05-03

Similar Documents

Publication Publication Date Title
US6448233B1 (en) Topical application of a combination of benzoyl peroxide and a second active ingredient
DE69827138T2 (en) Sterile retinoid-containing biodegradable implant with improved biocompatibility and process for its preparation
AU2010212478B2 (en) Non-aqueous single phase vehicles and formulations utilizing such vehicles
US5064655A (en) Liposome gel composition and method
EP3034072B1 (en) Controlled-release ophthalmic vehicles
US5466446A (en) Topical compositions containing bensoyl peroxide and clindamycin and method of use thereof
CA2647127A1 (en) Foamable suspension gel
CA2211006A1 (en) Topically applied pharmaceutical composition, method of preparing it and its use
WO2000027353A1 (en) Skin care composition
AU730953B2 (en) Aqueous suspension for nasal administration
US20030044432A1 (en) Acne treating composition
WO2001085129A2 (en) Skin care composition
AU775500B2 (en) Preparations for the application of anti-infective and/or anti-inflammatory agents
AU608268B2 (en) Nasal solutions
JP2002114711A (en) External preparation composition
WO2001091726A1 (en) Acne-treating composition
EP1809244B1 (en) Retinoid solutions and formulations made therefrom

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 98807022.7

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 1998945191

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1020007000068

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 09462384

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1998945191

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: CA

WWP Wipo information: published in national office

Ref document number: 1020007000068

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 1998945191

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: 1020007000068

Country of ref document: KR